NASDAQ:RVLP - Nasdaq - IE00BF2HDL56 - Common Stock - Currency: USD
0.0282
-0.01 (-32.05%)
The current stock price of RVLP is 0.0282 USD. In the past month the price decreased by -71.8%. In the past year, price decreased by -98.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 125 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The firm is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
RVL PHARMACEUTICALS PLC
400 Crossing Boulevard
Bridgewater NEW JERSEY US
Employees: 125
Company Website: https://www.rvlpharma.com/
Phone: 19088091300.0
The current stock price of RVLP is 0.0282 USD. The price decreased by -32.05% in the last trading session.
The exchange symbol of RVL PHARMACEUTICALS PLC is RVLP and it is listed on the Nasdaq exchange.
RVLP stock is listed on the Nasdaq exchange.
9 analysts have analysed RVLP and the average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282. Check the RVL PHARMACEUTICALS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RVL PHARMACEUTICALS PLC (RVLP) has a market capitalization of 3.14M USD. This makes RVLP a Nano Cap stock.
RVL PHARMACEUTICALS PLC (RVLP) currently has 125 employees.
The Revenue of RVL PHARMACEUTICALS PLC (RVLP) is expected to decline by -28.9% in the next year. Check the estimates tab for more information on the RVLP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RVLP does not pay a dividend.
RVL PHARMACEUTICALS PLC (RVLP) will report earnings on 2023-11-08, before the market open.
RVL PHARMACEUTICALS PLC (RVLP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
ChartMill assigns a fundamental rating of 2 / 10 to RVLP. Both the profitability and financial health of RVLP have multiple concerns.
Over the last trailing twelve months RVLP reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 27.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -79.93% | ||
ROE | -418.14% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to RVLP. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 27.9% and a revenue growth -28.9% for RVLP